NCT05970302View on ClinicalTrials.gov

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions
TislelizumabBevacizumabOxaliplatinCapecitabineMSS/pMMRMetastatic Colorectal Cancer (mCRC)RAS-mutatedFirst-Line
Interventions
DRUG

Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine

Use the above medications on a regular basis.

Trial Locations (1)

Unknown

RECRUITING

Lin Yang, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER